Real-World Cannabis Drug Interactions: A Systematic Review Found 31 Documented Cases with Serious Medications | Research

The takeaway

After screening 4,600 reports, researchers identified 31 documented cases of clinically significant drug interactions between cannabinoids and narrow-therapeutic-index medications — including warfarin, clobazam, and tacrolimus.

Read this if you use cannabis and take warfarin, anti-seizure medications, immunosuppressants, or other medications where precise dosing is critical.

What the researchers found

This systematic review went hunting for something specific: documented real-world cases where cannabis or cannabinoids caused clinically significant interactions with prescription medications that have narrow therapeutic windows — drugs where even small changes in blood levels can cause serious harm.

After screening 4,600 reports, they identified 31 cases meeting their criteria. This may seem like a small number, but it reflects the current state of documentation, not the actual frequency of interactions. Drug interactions with cannabis are almost certainly massively underreported because most patients don't tell their prescribers about cannabis use and most prescribers don't ask.

The medications involved read like a list of drugs you really don't want to get wrong: warfarin (blood thinner — too much causes bleeding), clobazam (anti-seizure — too much causes excessive sedation), tacrolimus (immunosuppressant for transplant patients — too much causes organ toxicity, too little causes rejection). The interactions were primarily mediated through CYP3A4, CYP2C9, and CYP2C19 — the same enzyme pathways identified in the controlled studies (RTHC-00091) and in vitro research (RTHC-00104).

The review specifically focused on delta-9-THC, CBD, and whole cannabis — but noted that delta-8-THC and other cannabinoids likely have similar interaction potential. The predicted mechanism (CYP enzyme inhibition) matched the observed interactions in most cases, validating the in vitro findings with real-world clinical consequences.

Why it matters

This review bridges the gap between theoretical drug interactions (shown in vitro) and actual patient harm. The 31 cases prove that cannabis drug interactions aren't just a laboratory concern — they cause real clinical problems including excessive anticoagulation, oversedation, and altered immunosuppressant levels. The systematic approach also reveals how few interactions are actually documented, suggesting the true burden is much larger.

The numbers in context

4,600 reports screened. 151 full-text articles assessed. 31 documented interaction cases identified. Key medications involved: warfarin, clobazam, tacrolimus, and others with narrow therapeutic indices. Primary mechanisms: CYP3A4, CYP2C9, CYP2C19 inhibition.

How the study worked

Systematic review of all years through 2023, searching for documented drug-drug interactions between cannabinoids (delta-9-THC, CBD, cannabis) and a pre-specified list of prescription medications with narrow therapeutic indices. 4,600 reports screened, 151 full-text articles assessed, 31 reports meeting inclusion/exclusion criteria identified.

Who was studied

N=889 individuals, including 603 cannabis/cannabinoid users, from various reports on drug-drug interactions.

What this study cannot tell us

Only 31 cases identified — almost certainly a vast undercount due to underreporting. Case reports are the weakest form of evidence for establishing causation (many factors could contribute to changing drug levels). The pre-specified list of narrow-therapeutic-index drugs may have missed other relevant interactions. Cannabis product composition was often poorly documented in case reports. Publication bias favors dramatic cases over subtle interactions.

How to read the evidence

Systematic review with rigorous methodology, but the underlying evidence consists of case reports and case series — the weakest level of clinical evidence. The consistent mechanism (CYP inhibition) across cases strengthens the overall picture.

When this study was published

Published in 2024. As cannabis use grows and prescribers become more aware, documentation of drug interactions should increase.

The bigger picture

This is the systematic evidence that ties the entire drug interaction cluster together. RTHC-00091 showed enzyme inhibition in a controlled trial. RTHC-00104 showed it in vitro with blood thinners. RTHC-00112 mapped the theoretical landscape. Now this review confirms 31 real-world cases where patients were harmed. The cascade from mechanism to real-world consequence is complete: cannabinoids inhibit CYP enzymes → co-administered drugs accumulate → patients experience adverse effects.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

How many cannabis drug interactions go unrecognized and unreported? Should pharmacies implement cannabis interaction screening when patients fill prescriptions? At what cannabis dose/frequency do clinically meaningful interactions begin? Should transplant patients, anticoagulated patients, and epilepsy patients be specifically counseled about cannabis interaction risk?

Read the original research

Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis.

Frontiers in pharmacology, 15, 1282831

Frontiers in Pharmacology is a reputable journal known for publishing high-quality research in the field of pharmacology.

View on PubMed ↗Publisher’s paper ↗

Citation

Nachnani, Rahul; Knehans, Amy; Neighbors, Jeffrey D; Kocis, Paul T; Lee, Tzuo; Tegeler, Kayla; Trite, Thomas; Raup-Konsavage, Wesley M; Vrana, Kent E. (2024). Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis.. Frontiers in pharmacology, 15, 1282831. https://doi.org/10.3389/fphar.2024.1282831